Please login to the form below

Not currently logged in
Email:
Password:

sleep disorders

This page shows the latest sleep disorders news and features for those working in and with pharma, biotech and healthcare.

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

Axovant’s lead candidate now is nelotanserin, a 5-HT2a receptor inverse agonist in phase II trials as a treatment for visual hallucinations and sleep disorders in Lewy body dementia and

Latest news

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    This has proved to be the case following Teva's purchase of Cephalon in May 2011 for $6.2bn which brought Provigil (modafinil for sleep disorders) into the portfolio. ... The paediatric PRV was issued when Cholbam was approved for the treatment of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Neurodiversity, ADHD and work: Obstacles and opportunities

    they generally persist through to adulthood, leading to on average worse educational, occupational, economic, social and relationship outcomes,[3] with higher rates of comorbidities such as mood, anxiety and sleep ... Functional impairment and

  • Clark Health Communications unveils new positioning

    in multiple areas of women’s health and in prostate cancer, haemophilia, sleep/breathing disorders, health informatics and medical diagnostic services and UK programmes in mental health, women’s health and

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics